Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 48, 2014 - Issue 6
Journal homepage
415
Views
5
CrossRef citations to date
0
Altmetric
Original Articles

Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII

Arto J. SalonenDepartment of Urology, Kuopio University Hospital, Kuopio, FinlandCorrespondence[email protected]
,
Kimmo TaariDepartment of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
,
Martti Ala-OpasDepartment of Urology and
,
Anna SankilaHUSLAB, Division of Pathology, Helsinki University Hospital, Helsinki, Finland
,
Jouko ViitanenDepartment of Urology, Pohjois-Karjala Central Hospital, Joensuu, Finland
,
Seppo LundstedtDepartment of Urology, Keski-Suomi Central Hospital, Jyväskylä, Finland
,
Teuvo L. J. TammelaDepartment of Surgery, Tampere University Hospital, and School of Medicine, University of Tampere, Tampere, Finland
& The Finnprostate Group show all
Pages 513-522 | Received 29 Nov 2013, Accepted 25 Feb 2014, Published online: 31 Mar 2014

References

  • Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL, et al. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation. J Urol 2008;180:915–19; discussion 919–20.
  • Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela T, et al. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J Urol 2012;187:2074–81.
  • Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TLJ, et al. Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects. Eur Urol 2013;63:111–20.
  • Cleary PD, Morrissey G, Oster G. Health-related quality of life in patients with advanced prostate cancer: a multinational perspective. Qual Life Res 1995;4:207–20.
  • Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582–92.
  • Albrecht W, Collette L, Fava C, Kariakine OB, Whelan P, Studer UE, et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. Eur Urol 2003;44:505–11.
  • Prapotnich D, Fizazi K, Escudier B, Mombet A, Cathala N, Vallancien G. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003;43:233–40.
  • De La Taille A, Zerbib M, Conquy S, Amsellem-Ouazana D, Thiounn N, Flam TA, et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int 2003;91:18–22.
  • Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, de Reijke T, et al. Using PSA to guide timing of androgen deprivation in patients with T0–4 N0–2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941–9.
  • Langenhuijsen JF, Badhauser D, Schaaf B, Kiemeney LA, Witjes JA, Mulders PF. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer. Urol Oncol 2013;31:549–56.
  • de Leval J, Boca P, Youssef E, Nicolas H, Jeukenne M, Seidel L, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002;1:163–71.
  • Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009;55:1269–77.
  • Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A, Wolff JM. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial. BJU Int 2012;110:1262–9.
  • Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;368:1314–25.
  • Verhagen PCMS, Wissenburg LD, Wildhagen MF, Bolle WABM, Verkerk AM, Schröder FH, et al. Quality of life effects of intermittent and continuous hormonal therapy by cyproterone acetate (CPA) for metastatic prostate cancer (abstract 541). Eur Urol Suppl 2008;7:206.
  • Herr HW, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000;163:1743–6.
  • Kato T, Komiya A, Suzuki H, Imamoto T, Ueda T, Ichikawa T. Effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancer. Int J Urol 2007;14:416–21.
  • Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722–30.
  • Niraula S, Le LW, Tannock IF. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol 2013;31:2029–36.
  • Klotz L. Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer. Curr Urol Rep 2013;14:159–67.
  • Tsai HT, Penson DF, Makambi KH, Lynch JH, Van Den Eeden SK, Potosky AL. Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. Urology 2013;82:327–33.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.